Figure 7.
Figure 7. PI4KIIIβ regulates PI4P and ATG9A trafficking. (A) HEK293A cells were treated with RF or PI4KIIIβ siRNA for 72 h, incubated in FM or ES for 2 h, and immunostained for PI4P and GM130. Scale bars, 10 µm. (B) HEK293A cells were treated with RF or PI4KIIIβ siRNA for 72 h and then incubated in FM or ES for 2 h, fixed, and labeled using antibody to ATG9A and GM130. Scale bars, 10 µm. (C) Quantification of ATG9A and GM130 colocalization in B; statistical analysis using one-way ANOVA with Tukey’s multiple comparisons test, mean ± SEM, n = 3 experiments, Pearson’s coefficient of 30 cells per condition per independent experiment were quantified; *, P ≤ 0.05; ***, P ≤ 0.0.001. (D) HEK293A cells were treated with RF or PI4KIIIβ siRNA for 72 h, incubated in FM or ES for 2 h, fixed, and labeled using antibodies to ARFIP2 and TGN46. Scale bars, 10 µm.

PI4KIIIβ regulates PI4P and ATG9A trafficking. (A) HEK293A cells were treated with RF or PI4KIIIβ siRNA for 72 h, incubated in FM or ES for 2 h, and immunostained for PI4P and GM130. Scale bars, 10 µm. (B) HEK293A cells were treated with RF or PI4KIIIβ siRNA for 72 h and then incubated in FM or ES for 2 h, fixed, and labeled using antibody to ATG9A and GM130. Scale bars, 10 µm. (C) Quantification of ATG9A and GM130 colocalization in B; statistical analysis using one-way ANOVA with Tukey’s multiple comparisons test, mean ± SEM, n = 3 experiments, Pearson’s coefficient of 30 cells per condition per independent experiment were quantified; *, P ≤ 0.05; ***, P ≤ 0.0.001. (D) HEK293A cells were treated with RF or PI4KIIIβ siRNA for 72 h, incubated in FM or ES for 2 h, fixed, and labeled using antibodies to ARFIP2 and TGN46. Scale bars, 10 µm.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal